Allogene initiates Phase 2 ALPHA2 trial of ALLO-501A in r/r LBCL; plans EXPAND trial for ALLO-647

Allogene Therapeutics, Inc.

ALPHA2 trial will enroll ~100 r/r LBCL patients with single 120M CAR+ cell dose; primary endpoint ORR.
EXPAND trial (~70 patients) randomized to assess ALLO-647 contribution to lymphodepletion regimen.
FDA cleared manufacturing from CF1 using non-Alloy process; Alloy process being implemented at CF1.
Company plans to seek FDA approval based on ALPHA2 and EXPAND trials assuming favorable outcomes.
CD19 program update, including longer-term Phase 1 follow-up with Alloy process, expected end of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.